Company intelligence / Profile preview

Yuxi Walvax Biotechnology

Yuxi, Yunnan, China

Ownership: Private
Employees: ~2500
Development stage: Other

Overview

Walvax has successfully commercialized several high-impact vaccines in China, including the first domestic 13-valent pneumococcal conjugate vaccine (Weitairuo) and a bivalent HPV vaccine (Walrinvax). Their mRNA COVID-19 vaccine, AWcorna, received emergency use authorization in several countries.

Therapeutic areas: OncologyInfectious Diseases
Modalities: VaccinemRNA-based drugsRecombinant proteinConjugate vaccinePolysaccharide vaccine
Industry: Biotech

Partnerships

Abogen BiosciencesAcademy of Military Medical SciencesCEPI

Beyond the preview

Go deeper on Yuxi Walvax Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yuxi Walvax Biotechnology.

Explore the full profile